Literature DB >> 30851443

Immune Checkpoint Inhibitor-Associated Pericarditis.

Mehmet Altan1, Maria I Toki2, Scott N Gettinger3, Daniel E Carvajal-Hausdorf4, Jon Zugazagoitia2, John H Sinard2, Roy S Herbst3, David L Rimm5.   

Abstract

Side effects of immune checkpoint inhibitors, termed immune-related adverse events, are relatively common, but immune checkpoint inhibitor-mediated cardiotoxicities are rare; however, they can be serious and potentially fatal. Pericarditis is an infrequent cardiac toxicity of immunotherapy and predisposing factors remain unknown. Here we report three patients with NSCLC who developed pericarditis during therapy with programmed death 1/programmed death ligand 1+/- CTLA-4 inhibitors. We review the clinical presentation of these three cases and histopathologic findings from autopsies from the first two patients and a pericardial sampling that has been obtained from a pericardial window procedure in the third patient who recovered from the pericarditis episode. We also discuss the potential mechanisms, as well as what is known about pericarditis secondary to immune-related adverse events.
Copyright © 2019 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Immune-related adverse events; NSCLC; Pericarditis

Mesh:

Substances:

Year:  2019        PMID: 30851443      PMCID: PMC6617516          DOI: 10.1016/j.jtho.2019.02.026

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  15 in total

Review 1.  Clinical practice. Acute pericarditis.

Authors:  Martin M LeWinter
Journal:  N Engl J Med       Date:  2014-12-18       Impact factor: 91.245

2.  Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.

Authors:  Yukihiro Toi; Shunichi Sugawara; Jun Sugisaka; Hirotaka Ono; Yosuke Kawashima; Tomoiki Aiba; Sachiko Kawana; Ryohei Saito; Mari Aso; Kyoji Tsurumi; Kana Suzuki; Hisashi Shimizu; Yutaka Domeki; Keisuke Terayama; Atsushi Nakamura; Shinsuke Yamanda; Yuichiro Kimura; Yoshihiro Honda
Journal:  JAMA Oncol       Date:  2019-03-01       Impact factor: 31.777

3.  Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor-Related Cardiotoxicity.

Authors:  Marion Escudier; Jennifer Cautela; Nausicaa Malissen; Yann Ancedy; Morgane Orabona; Johan Pinto; Sandrine Monestier; Jean-Jacques Grob; Ugo Scemama; Alexis Jacquier; Nathalie Lalevee; Jeremie Barraud; Michael Peyrol; Marc Laine; Laurent Bonello; Franck Paganelli; Ariel Cohen; Fabrice Barlesi; Stephane Ederhy; Franck Thuny
Journal:  Circulation       Date:  2017-11-21       Impact factor: 29.690

4.  Myocarditis in Patients Treated With Immune Checkpoint Inhibitors.

Authors:  Syed S Mahmood; Michael G Fradley; Justine V Cohen; Anju Nohria; Kerry L Reynolds; Lucie M Heinzerling; Ryan J Sullivan; Rongras Damrongwatanasuk; Carol L Chen; Dipti Gupta; Michael C Kirchberger; Magid Awadalla; Malek Z O Hassan; Javid J Moslehi; Sachin P Shah; Sarju Ganatra; Paaladinesh Thavendiranathan; Donald P Lawrence; John D Groarke; Tomas G Neilan
Journal:  J Am Coll Cardiol       Date:  2018-03-19       Impact factor: 24.094

5.  Fulminant Myocarditis with Combination Immune Checkpoint Blockade.

Authors:  Douglas B Johnson; Justin M Balko; Margaret L Compton; Spyridon Chalkias; Joshua Gorham; Yaomin Xu; Mellissa Hicks; Igor Puzanov; Matthew R Alexander; Tyler L Bloomer; Jason R Becker; David A Slosky; Elizabeth J Phillips; Mark A Pilkinton; Laura Craig-Owens; Nina Kola; Gregory Plautz; Daniel S Reshef; Jonathan S Deutsch; Raquel P Deering; Benjamin A Olenchock; Andrew H Lichtman; Dan M Roden; Christine E Seidman; Igor J Koralnik; Jonathan G Seidman; Robert D Hoffman; Janis M Taube; Luis A Diaz; Robert A Anders; Jeffrey A Sosman; Javid J Moslehi
Journal:  N Engl J Med       Date:  2016-11-03       Impact factor: 91.245

6.  Suspected autoimmune myocarditis and cardiac conduction abnormalities with nivolumab therapy for non-small cell lung cancer.

Authors:  Robert Gibson; Jess Delaune; Anita Szady; Merry Markham
Journal:  BMJ Case Rep       Date:  2016-07-20

7.  Programmed death ligand 1 regulates a critical checkpoint for autoimmune myocarditis and pneumonitis in MRL mice.

Authors:  Julie A Lucas; Julia Menke; Whitney A Rabacal; Frederick J Schoen; Arlene H Sharpe; Vicki R Kelley
Journal:  J Immunol       Date:  2008-08-15       Impact factor: 5.422

8.  Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.

Authors:  Daniel Y Wang; Joe-Elie Salem; Justine V Cohen; Sunandana Chandra; Christian Menzer; Fei Ye; Shilin Zhao; Satya Das; Kathryn E Beckermann; Lisa Ha; W Kimryn Rathmell; Kristin K Ancell; Justin M Balko; Caitlin Bowman; Elizabeth J Davis; David D Chism; Leora Horn; Georgina V Long; Matteo S Carlino; Benedicte Lebrun-Vignes; Zeynep Eroglu; Jessica C Hassel; Alexander M Menzies; Jeffrey A Sosman; Ryan J Sullivan; Javid J Moslehi; Douglas B Johnson
Journal:  JAMA Oncol       Date:  2018-12-01       Impact factor: 31.777

9.  Upregulation of Programmed Death-1 and Its Ligand in Cardiac Injury Models: Interaction with GADD153.

Authors:  Babak Baban; Jun Yao Liu; Xu Qin; Neal L Weintraub; Mahmood S Mozaffari
Journal:  PLoS One       Date:  2015-04-22       Impact factor: 3.240

10.  PD-1 Modulates Radiation-Induced Cardiac Toxicity through Cytotoxic T Lymphocytes.

Authors:  Shisuo Du; Lin Zhou; Gregory S Alexander; Kyewon Park; Lifeng Yang; Nadan Wang; Nicholas G Zaorsky; Xinliang Ma; Yajing Wang; Adam P Dicker; Bo Lu
Journal:  J Thorac Oncol       Date:  2017-12-13       Impact factor: 20.121

View more
  26 in total

Review 1.  Cancer Treatment-Associated Pericardial Disease: Epidemiology, Clinical Presentation, Diagnosis, and Management.

Authors:  Chandra K Ala; Allan L Klein; Javid J Moslehi
Journal:  Curr Cardiol Rep       Date:  2019-11-25       Impact factor: 2.931

2.  Immune checkpoint inhibitors-associated pericardial disease: a systematic review of case reports.

Authors:  Alessandro Inno; Nicola Maurea; Giulio Metro; Andreina Carbone; Antonio Russo; Stefania Gori
Journal:  Cancer Immunol Immunother       Date:  2021-04-20       Impact factor: 6.968

Review 3.  [Novel cancer treatment and the cardiovascular risk : What should cardiologists know?]

Authors:  Matthias Totzeck; Tienush Rassaf
Journal:  Herz       Date:  2020-04       Impact factor: 1.443

Review 4.  Exploring the Mechanisms Underlying the Cardiotoxic Effects of Immune Checkpoint Inhibitor Therapies.

Authors:  Daniel Ronen; Aseel Bsoul; Michal Lotem; Suzan Abedat; Merav Yarkoni; Offer Amir; Rabea Asleh
Journal:  Vaccines (Basel)       Date:  2022-03-31

Review 5.  What the Cardiologist Needs to Know About Cancer Immunotherapies and Complications.

Authors:  Marina Frayberg; Anthony Yung; Leyre Zubiri; Daniel A Zlotoff; Kerry L Reynolds
Journal:  Curr Treat Options Oncol       Date:  2021-05-26

Review 6.  Mechanisms of Cardiovascular Toxicities Associated With Immunotherapies.

Authors:  Alan H Baik; Olalekan O Oluwole; Douglas B Johnson; Nina Shah; Joe-Elie Salem; Katy K Tsai; Javid J Moslehi
Journal:  Circ Res       Date:  2021-05-03       Impact factor: 23.213

Review 7.  Cardiotoxicity from immune checkpoint inhibitors.

Authors:  Lars Michel; Tienush Rassaf; Matthias Totzeck
Journal:  Int J Cardiol Heart Vasc       Date:  2019-09-07

Review 8.  Mechanisms and clinical manifestations of cardiovascular toxicities associated with immune checkpoint inhibitors.

Authors:  Alan H Baik; Katy K Tsai; David Y Oh; Mandar A Aras
Journal:  Clin Sci (Lond)       Date:  2021-03-12       Impact factor: 6.124

Review 9.  Myocarditis Induced by Immune Checkpoint Inhibitors: Mechanisms and Therapeutic Prospects.

Authors:  Wenlu Zou; Jie Lu; Yan Hao
Journal:  J Inflamm Res       Date:  2021-07-08

10.  Pericardial disease in patients treated with immune checkpoint inhibitors.

Authors:  Jingyi Gong; Zsofia Dora Drobni; Amna Zafar; Thiago Quinaglia; Sarah Hartmann; Hannah K Gilman; Vineet K Raghu; Carlos Gongora; Meghan E Sise; Raza M Alvi; Leyre Zubiri; Anju Nohria; Ryan Sullivan; Kerry L Reynolds; Daniel Zlotoff; Tomas G Neilan
Journal:  J Immunother Cancer       Date:  2021-06       Impact factor: 13.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.